Use your browser's back button to choose another title or click here for a New Search.

How to Get the Article

 Email CTN Library (free)

PubMed Central (free)

Journal subscriber access




Bookmark and Share


Predictors of Abstinence: National Institute of Drug Abuse Multisite Buprenorphine/Naloxone Treatment Trial in Opioid-Dependent Youth.

Journal of the American Academy of Child & Adolescent Psychiatry 2001;50(11):1120-1128. [doi: 10.1016/j.jaac.2011.07.010]

Geetha A. Subramaniam, MD (Mountain Manor Treatment Center, MA Node), Diane Warden, PhD, MBA (University of Texas Southwestern Medical Center, TX Node), Abu Minhajuddin, PhD (University of Texas Southwestern Medical Center, TX Node), Marc J. Fishman, MD (Mountain Manor Treatment Program, MA Node), Maxine L. Stitzer, PhD (Johns Hopkins University School of Medicine, MA Node), Bryon H. Adinoff, MD (University of Texas Southwestern Medical Center, TX Node), Madhukar H. Trivedi, MD (University of Texas Southwestern Medical Center, TX Node), Roger D. Weiss, MD (McLean Hospital, NEC Node), Jennifer Sharpe Potter, MPH, PhD (McLean Hospital, Harvard Medical School, NEC Node), Sabrina A. Poole, MS (University of Pennsylvania School of Medicine, DV Node), George E. Woody, MD (University of Pennsylvania School of Medicine, DV Node).

Prescription opioids are second only to marijuana as the most commonly used illicit substances among high school seniors. Buprenorphine, a partial mu-agonist, has shown promise in treating opioid-dependent youth in two recent NIDA-funded studies, including a multisite trial in the National Drug Abuse Treatment Clinical Trials Network (CTN-0010, "Buprenorphine/Naloxone-Facilitated Rehabilitation for Opioid Dependent Adolescents/Young Adults"). This ancillary investigation of data from that study, which compared 12 weeks of extended buprenorphine/naloxone (Bup/Nal) therapy to 2 weeks of Bup/Nal detoxification in youth ages 15-21, aimed to examine predictors of opioid abstinence in Bup/Nal-assisted psychosocial treatment for opioid-dependent youth. Results found that youth presenting to treatment with previous 30-day injection drug use and more active medical/psychiatric problems were less likely to have a week-12 opioid-positive urine (OPU). Those with early treatment abstinence (i.e., weeks 1 and 2) and those who received additional nonstudy treatments during the study were less likely to have a week-12 OPU and those not completing 12 weeks of treatment were more likely to have an OPU.

Conclusions: Youth with advanced illness (i.e., reporting injection drug use and additional health problems) and those receiving ancillary treatments to augment study treatment were more likely to have lower opioid use. Treatment success in the first 2 weeks and completion of 12 weeks of treatment were associated with lower rates of opioid-positive urines. These findings suggest that youth with advanced illness respond well to Bup/Nal treatment and identify options for tailoring treatment for opioid-dependent youth presenting at community-based settings. (Article (Peer-Reviewed), PDF, English, 2011)

Keywords: Adolescents | Buprenorphine/Naloxone | CTN platform/ancillary study | Opioid dependence | Opioid detoxification | Pharmacological therapy | Suboxone | Young adults | Journal of the American Academy of Child and Adolescent Psychiatry (journal)

Document No: 706, PMID: 22024000, PMCID: PMC3786351.

Submitted by the Jack Blaine, Publications Committee, 11/5/2008.

Adinoff, Bryon H. search mail
Fishman, Marc J. search mail
Minhajuddin, Abu search
Poole, Sabrina A. search mail
Potter, Jennifer Sharpe search mail
Stitzer, Maxine L. search mail
Subramaniam, Geetha A. search mail
Trivedi, Madhukar H. search mail
Warden, Diane search mail
Weiss, Roger D. search mail
Woody, George E. search mail
NIDA-CTN-0010 search www
Delaware Valley (Lead) search www
Mid-Atlantic search www
New England Consortium search www
North Carolina search www
Southwest search www

Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 10/2013 --